A Phase II Trial of Weekly Docetaxel and Bortezomib (Velcade; PS-341) in the Treatment of Patients With Advanced Hormone-Refractory Prostate Cancer
Upon determination of eligibility, patients will be receive:
- Docetaxel + Bortezomib
Patients with objective responses or stable disease will continue treatment for eight
courses or until disease progression is documented.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
objective response rate
John D. Hainsworth, MD
Principal Investigator
Sarah Cannon Research Institute
United States: Food and Drug Administration
SCRI GU 18
NCT00193232
May 2004
February 2007
Name | Location |
---|